Androgen deprivation therapy: indications, methods of utilization, side effects and their management.

Androgen deprivation therapy: indications, methods of utilization, side effects and their management. Can J Urol. 2020 Feb;27(1S1):11-16 Authors: Magee DE, Singal RK Abstract Our objective is to provide an up-to-date summary of current literature on the indications for androgen deprivation therapy (ADT), ways in which ADT is used, and the main side effects associated with its use. MEDLINE (Pubmed) was searched for relevant papers published from database inception to May 1, 2019 for studies evaluating the use of ADT and its associated adverse events. ADT is a mainstay in the treatment of prostate cancer and is used throughout the disease course. While predominantly used in the metastatic setting, ADT has a role in the treatment of localized disease and in the management of recurrent cancer. Intermittent ADT has an application for a certain subset of men with recurrent and metastatic disease who have significant side effects. Associated side effects of ADT are wide ranging and include osteoporosis with an associated increased fracture risk, elevated rates of diabetes, metabolic syndrome, cardiovascular risk, sexual dysfunction and hot flashes. As ADT has a variety of associated side effects, care for men receiving ADT is best managed in a multidisciplinary setting with active participation between the treating physician (urologist, radiation oncologist) and their primary care physician. PMID: 32101695 [PubMed - in process]
Source: Canadian Journal of Urology - Category: Urology & Nephrology Tags: Can J Urol Source Type: research

Related Links:

I am a Canadian student, I am finishing my biology degree this year and I have unfortunately not been accepted into any schools so far (Applied to 9, 3 haven't replied yet but I am assuming they've denied me). I wasn't even able to get an interview... I have pretty standard/below average extracurriculars, nothing too special, my GPA is about 3.25~ and for the DAT I took it twice with the second attempt landing me AA: 19 TS: 19 with a shocking 15 in PAT. Canadian schools are too competitive... Looking for some advice regarding what I should do after being rejected
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Pre-Dental Source Type: forums
CONCLUSIONS These results indicate that GDLP against T2DM-induced hepatic steatosis, oxidative stress, and inflammation by improving the Nrf2/HO-1 signaling pathway in db/db mice, suggesting the GDLP may serve as an effective strategy for in fatty liver treatment. PMID: 32245940 [PubMed - as supplied by publisher]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Foods high in soluble fiber like oatmeal, nuts and beans were associated with reduced breast cancer incidence.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Breast Cancer Diet and Nutrition Fiber (Dietary) Source Type: news
Publication date: Available online 4 April 2020Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Kaili Wang, Weijie Zhang, Zihan Wang, Ming Gao, Xinying Wang, Wenchao Han, Nan Zhang, Xia Xu
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 4 April 2020Source: Journal of Ayurveda and Integrative MedicineAuthor(s): Naresh Kumar P, Ragavendrasamy Balakrishnan, Vibhas Kana
Source: Journal of Ayurveda and Integrative Medicine - Category: Complementary Medicine Source Type: research
Publication date: Available online 5 April 2020Source: Seminars in Cancer BiologyAuthor(s): Emad A. Rakha, Fresia G. Pareja
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 4 April 2020Source: Seminars in Cancer BiologyAuthor(s): Michela Biancolella, Barbara Testa, Leila Baghernajad Salehi, Maria Rosaria D’Apice, Giuseppe Novelli
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 4 April 2020Source: Seminars in Cancer BiologyAuthor(s): Jyoti Gupta, Haaris Ahsan Safdari, Mehboob Hoque
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Here, we present what, to the best of our knowledge, is the first reported case in which durvarumab resistance after definitive chemoradiotherapy in a patient with stage III pulmonary sarcomatoid carcinoma was overcome by pembrolizumab. PMID: 32245391 [PubMed - as supplied by publisher]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Databases & Libraries | Diabetes | Endocrinology | Heart | Metabolic Syndrome | Orthopaedics | Osteoporosis | Primary Care | Prostate Cancer | Sexual Dysfunction | Study | Urology & Nephrology